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Nasopharyngeal carcinoma (NPC) is one of the most
common malignant neoplasms of the head and neck
region in Taiwan [1]. Although disease-free and higher
overall survival rate of patients with NPC can be
achieved with early diagnosis and combined radio-
therapy and chemotherapy [2,3], these patients, and
particularly those with oral cancer, are at increased
risk of developing second primary epithelial malignan-
cies due to the field metastasis phenomenon [4–10].
Small cell neuroendocrine carcinoma (SNEC) is a
malignancy that typically occurs in the lung, although
rare cases of primary SNEC in the head and neck
region have been reported [4–11]. SNEC can also occur
in the upper aerodigestive tract, including the nasal
cavities, paranasal sinuses, oral cavity, salivary glands,
pharynx, larynx, trachea and thyroid glands [12]. SNEC
of the nasal cavity displays a capacity for aggressive
local invasion, has a high recurrence rate and is asso-
ciated with poor prognosis [12]. Treatment options in-
clude surgical excision, multiple-agent chemotherapy
and radiation therapy. We report a rare case of primary
SNEC of the nasal cavity that developed in a patient
who was in complete remission of NPC following
chemotherapy 10 years earlier. Complete remission
of the primary SNEC was achieved with concurrent
chemoradiotherapy, and the patient showed no evi-
dence of disease during the 12 months of follow-up.
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Patients with head and neck cancer have a greater risk of developing second primary malignant
neoplasms than patients with any other type of malignancy. Small cell neuroendocrine carcinoma
(SNEC) mainly occurs in the lung, and is rarely found in the head and neck region. Only a few
cases of sinonasal SNEC have been reported in the English literature. A woman aged 53 years,
who had undergone successful curative radiotherapy for nasopharyngeal carcinoma 10 years
earlier, presented with a history of bleeding from the left nostril for several weeks. A computed
tomography scan of the head and neck showed a mass in the left nasal cavity with extension into
the maxillary sinus. A biopsy specimen was taken and pathology revealed SNEC. The patient
underwent a full course of concurrent chemoradiotherapy. No local recurrence or distant metastasis
was noted during the 12 months of follow-up.
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CASE PRESENTATION
A non-smoking woman aged 53 years presented with
a 3-week history of left-sided epistaxis. Her medical
history was notable for NPC (T4N0M0), which had
been treated successfully with radiotherapy 10 years
earlier. She had no facial pain, dysphagia, odynopha-
gia, hoarseness or diplopia. On physical examination,
the patient had a full range of movement of both eyes
and there was no evidence of neck lymphadenopa-
thy. Direct nasopharyngoscopy revealed an exophytic
fleshy mass (about 5×3 cm) in her left nasal cavity.
Contrast-enhanced computed tomography (CT) of
the neck revealed an ill-defined mass in the left nasal
cavity extending laterally and superiorly to the sphe-
noid and maxillary sinuses (Figure 1). The tumor ap-
peared to have invaded the left orbital apex. There was
also fluid accumulation in the left maxillary sinus.
There was no evidence of metastasis to the neck
lymph nodes.
An incisional biopsy of the mass was performed.
Microscopic examination of the specimen showed 
an infiltrative tumor characterized by a diffused, solid
growth pattern in the deepest part of the chorion.
Hematoxylin and eosin staining of the biopsy speci-
men revealed small, monotonous, round blue neoplas-
tic cells with scant cytoplasm and “salt and pepper”
hyperchromatic nuclei with prominent apoptosis and
marked tumor necrosis (Figure 2A). Immunohisto-
chemical staining was positive for cytokeratin (CK)
(AE1/AE3) (Figure 2B), synaptophysin (Figure 2C),
and neuron-specific enolase (NSE) (Figure 2D). The
diagnosis of undifferentiated small cell carcinoma
(SCC) was confirmed.
To differentiate primary SCC from a metastatic
lung SCC, a plain chest X-ray and a high-resolution
chest CT scan were performed, but no definitive
lesions were detected. In addition, abdominal sonog-
raphy and a bone scan also excluded the possibility
of malignant metastasis.
The patient received six courses of chemotherapy
with VP-16 and cisplatin, monthly. Concomitant radio-
therapy using an intensive modulated radiotherapy
technique with 50 Gy in 2-Gy fractions was also ap-
plied. Following the completion of the six courses of
chemoradiotherapy, a CT scan and direct laryngoscopy
revealed no evidence of the disease. Six months after
completion of therapy, fluor-18-deoxyglucose-positron
emission tomography showed no residual disease
(Figure 3). Neither local recurrence nor distant meta-
stasis was noted during the 12 months of follow-up.
DISCUSSION
Although radiation therapy with curative intent is
the optimal treatment for patients with NPC, these
patients are still at risk of developing second primary
malignancies in the head and neck region [4–9]. The
incidence of second primary tumors developing in
patients with NPC after definitive treatment was
reported to be 0.7%, with onset occurring from 5–18
years after treatment [10]. Although the underlying
mechanisms are not well understood, there is much
cellular and molecular evidence supporting the theory
of field metastasis [4–9].
SNEC was first described as an “oat cell sarcoma”
by Barnard in 1926 [11], and accounts for 10–36% 
of all bronchogenic carcinomas [12]. Extrapulmonary
SNECs only account for 4% of all SNECs [13], and
very few cases of SNECs of head and neck have been
reported previously [14]. The most prevalent site of dis-
ease is the larynx; other sites include salivary glands,
paranasal sinus, parotid, hypopharynx and trachea
[15]. The majority of patients with SNEC of the head
and neck are male. Although there seems to be an
association with cigarette smoking, the association is
not as strong as that with pulmonary SNEC [12].
The symptoms of SNEC of the nasal cavity are
nonspecific and are similar to those of other sinonasal
Figure 1. Neck computed tomography shows an ill-defined soft-
tissue lesion in the left nasal cavity with extension into the left
sphenoid and maxillary sinuses.
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Figure 2. (A) Sheets of small blue cells with hyperchromatic nuclei and scanty cytoplasm are noted (hematoxylin & eosin, original
magnification, 400×). Immunohistochemical study was positive for: (B) cytokeratin (original magnification, 400×); (C) synaptophysin
(original magnification, 400×); and (D) neuron-specific enolase (original magnification, 400×). Arrows indicate tumor cells. 
tumors, such as epistaxis, nasal obstruction, facial
pain, diplopia, exophthalmos, proptosis, and limited
eye mobility [12,16]. The association between parane-
oplastic endocrine syndromes and SNEC is well doc-
umented, but they are rarely present in patients with
head and neck cancer. Only 20 cases of endocrine syn-
drome associated with head and neck SNECs have
been reported in the past [17]. Unlike pulmonary
SNECs, in which 17–47% of patients have bone mar-
row metastases, marrow involvement in patients with
SNECs of the nasal cavity is extremely rare [18].
The diagnosis of SNECs of the nasal cavity de-
pends on endoscopic findings, imaging studies and
pathologic evaluation of immunohistochemical char-
acteristics. Imaging studies, such as CT or magnetic
resonance imaging of the neck and nasal cavity can
provide information about inflammatory reactions,
anatomical location or tumor invasion. Positron emis-
sion tomography-CT can be used for primary tumor
staging and to monitor the effects of treatment [19].
The histological findings of SNECs reveal small round
cells with hyperchromatic nuclei and sparse cytoplasm
with a high nucleo-cytoplasmic ratio. Immunohisto-
chemically, these tumors are positive for cytokeratin
(AE1/AE3), CD56, synaptophysin and NSE, but neg-
ative for S-100 and neurofilaments. In this particular
patient, the tumor cells were immunohistochemically
positive for cytokeratin, synaptophysin and NSE, 
but negative for glial fibrillary acidic protein, CD3
and CD20.
Because of the rarity of SNECs of the nasal cavity,
the recommendations for treatment are based on ret-
rospective data and on comparative data for treatment
of SNECs of bronchogenic and other extrapulmonary
origin [12]. Surgery, radiotherapy and chemotherapy
are currently used for SNECs of the nasal cavity. In the
1980s, surgery followed by radiotherapy was favored;
however, since the late 1990s, the combination of che-
motherapy and radiotherapy, with or without surgery
has been recommended [12,15,20]. Cisplatin-based
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chemotherapy gives an effective response and is a
mandatory regimen for control of systemic relapses
[21]. However, the role of prophylactic brain irra-
diation is unclear. The patient received a six-course
cisplatin-based chemotherapy and radiotherapy regi-
men, and no local recurrence or distant metastasis
was noted during the 12 months of follow-up.
The prognosis of SNEC of the nasal cavity is very
poor because of the propensity for extensive local
infiltration and the high rate and early tendency for
distant metastases. The most common metastatic
locations are the brain, lungs, bones and skin [17].
Baugh et al reported that SNEC of the sinonasal region
had a propensity for local recurrence rather than early
metastasis, and that it was associated with a longer sur-
vival rate than SNECs at other sites. The paper also
reported a 1-year survival rate of 81% and a 5-year
survival rate of 71% for patients with SNEC of the
sinonasal region [22]. The median survival time has
been reported to range from 2 to 3 years [23].
In conclusion, SNEC of the nasal cavity is rare, but
can occur in patients after successful curative therapy
for NPC. The prognosis of SNEC is poor and long-term
follow-up is necessary. Prolonged survival can be achi-
eved if the disease is diagnosed early and treated
aggressively.
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神經內分泌癌的病例在英文文獻中被報告過。一名 53 歲的婦女，因鼻咽癌在 10 年前
接受成功的放射治療，有幾星期來從左鼻孔流出鼻血的病史。頭頸部的電腦斷層掃描
顯現一個在左鼻腔並伸入上頷骨靜脈竇的腫塊。我們採取了標本並做切片檢查，病理
上顯示了小細胞神經內分泌癌。患者接受了一完整的合併化學放射治療。經 12 個月
的追蹤並無局部復發或遠端的轉移。
關鍵詞：鼻腔，鼻咽癌，小細胞神經內分泌癌
(高雄醫誌 2009;25:145–50)
